RECRUITING

Impact of Depression on Thermoregulation

Talk to us

Conditions

DepressionSelective Serotonin Reuptake Inhibitorthermoregulationheat stressselective serotonin reuptake inhibitorsserotonin norepinephrine reuptake inhibitors

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine if, compared to non-depressed adults, differences exist in skin blood flow and sweating responses to passive heat stress in adults with clinically diagnosed depression, those with depression who are prescribed and taking SSRIs and those with depression who are prescribed and taking SNRIs.

Official Title

Thermoregulatory Responses to Heat Stress in Adults with Major Depressive Disorder with and Without Antidepressant Treatment

Quick Facts

Study Start:2025-03-01
Study Completion:2025-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06805851

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Non-depressed adults aged 18-40 years;
  2. * OR adults aged 18-40 years with clinically diagnosed major depressive disorder according to DSM-V criteria not currently receiving antidepressant treatment;
  3. * OR adults aged 18-40 years with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a selective serotonin reuptake inhibitor;
  4. * OR aged 18-40 years adults with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a serotonin norepinephrine reuptake inhibitor;
  5. * All participants will be asymptomatic and no signs/symptoms of disease according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription (chest pain or pressure, dizziness, joint pain, and signs of cardiovascular disease);
  6. * Systolic blood pressure 140 mmHg and diastolic pressure 90 mmHg at screening;
  7. * Non-diabetic
  8. * Not taking any other medications that might affect the physiological variables of interest (beta blockers, tricyclic antidepressants, antipyretics, diuretics, etc.);;
  9. * Between the 20th and 80th percentiles for sex- and age-appropriate VO2max according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription;
  10. * English proficiency;
  11. * Capable of providing informed consent.
  1. * BMI \> 35
  2. * Are pregnant or planning to become pregnant in the next 12 months;
  3. * Concurrently participate in another study involving physical activity or weight loss;
  4. * Plan to have surgery or relocate outside the area within the next year;
  5. * Medications that could alter cardiovascular or thermoregulatory responses to exercise (beta blockers, antipyretics, tricyclic antidepressants, diuretics, etc.);
  6. * Allergy to latex or adhesive;
  7. * Tobacco use;
  8. * Illegal/recreational drug use;
  9. * Exertional chest pain or musculoskeletal pain;
  10. * Contraindications to a maximal exercise test or an indication for early termination of the exercise test according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription;
  11. * Abnormal resting or exercise electrocardiogram (ECG);
  12. * Any bleeding disorders, gastric ulcers, allergies to NSAIDS, asthma, kidney/liver disorders, and taking any other anticoagulants;
  13. * History of Crohn's disease, diverticulitis, or similar gastrointestinal disease;
  14. * Co-morbid psychiatric disorders (psychosis, schizophrenia, bipolar disorder, panic disorder, obsessive compulsive disorder, etc.);
  15. * Active suicidal ideation (moderate or high suicidality);
  16. * Use of psychoactive or psychopharmacological drugs other than SSRI and SNRIs within one year of participating.

Contacts and Locations

Study Contact

W. Larry Kenney
CONTACT
814-863-1672
w7k@psu.edu
Kat G Fisher
CONTACT
3072037657
kgf5118@psu.edu

Principal Investigator

W. Larry Kenney
PRINCIPAL_INVESTIGATOR
The Pennsylvania State University

Study Locations (Sites)

Noll Laboratory
University Park, Pennsylvania, 16802
United States

Collaborators and Investigators

Sponsor: Penn State University

  • W. Larry Kenney, PRINCIPAL_INVESTIGATOR, The Pennsylvania State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-01
Study Completion Date2025-09-01

Study Record Updates

Study Start Date2025-03-01
Study Completion Date2025-09-01

Terms related to this study

Keywords Provided by Researchers

  • thermoregulation
  • heat stress
  • depression
  • selective serotonin reuptake inhibitors
  • serotonin norepinephrine reuptake inhibitors

Additional Relevant MeSH Terms

  • Depression
  • Selective Serotonin Reuptake Inhibitor